Coenzyme Q10 and selenium in statin-associated myopathy treatment

a Pavol Jozef Safarik University, 1st Department of Internal Medicine, Centre of Excellency for Atherosclerosis Research, Trieda SNP 1, 041 90 Kosice, Slovakia.
Canadian Journal of Physiology and Pharmacology (Impact Factor: 1.77). 02/2013; 91(2):165-70. DOI: 10.1139/cjpp-2012-0118
Source: PubMed


The objective of this study was to evaluate the possible benefits of coenzyme Q and selenium supplementation administered to patients with statin-associated myopathy (SAM). Sixty eligible patients entered the pilot study. Laboratory examination (CoQ10, selenium, creatin kinase) and intensity of SAM (visual scale) were performed at baseline, after 1 month, and at the end of study at month 3. Plasma levels of CoQ10 increased from 0.81 ± 0.39 to 3.31 ± 1.72 μmol/L in the active group of patients treated by CoQ10, compared with the placebo (p = 0.001). Also, the symptoms of SAM significantly improved in the active group (p < 0.001): the intensity of muscle pain decreased from 6.7 ± 1.72 to 3.2 ± 2.1 (p < 0.01, -53.4 ± 28.2%); muscle weakness decreased from 7.0 ± 1.63 to 2.8 ± 2.34 (p < 0.01, -60 ± 24.0%); muscle cramps decreased from 5.33 ± 2.06 to 1.86 ± 2.42, p < 0.01, -65 ± 28%); tiredness decreased from the initial 6.7 ± 1.34 to 1.2 ± 1.32 (p < 0.01, -82 ± 22%). We did not observe any significant changes in the placebo group. In conclusion, supplementation of statin-treated patients with CoQ10 resulted in a decrease in the symptoms of SAM, both in absolute numbers and intensity. Additional selenium supplementation was not associated with any statistically significant decrease of SAM. However, it is not possible to draw any definite conclusions, even though this study was carried out in double-blind fashion, because it involved a small number of patients.

Download full-text


Available from: Jan Fedacko,
  • [Show abstract] [Hide abstract]
    ABSTRACT: The National Lipid Association's Muscle Safety Expert Panel was charged with the duty of examining the definitions for statin-associated muscle adverse events, development of a clinical index to assess myalgia, and the use of diagnostic neuromuscular studies to investigate muscle adverse events. We provide guidance as to when a patient should be considered for referral to neuromuscular specialists and indications for the performance of a skeletal muscle biopsy. Based on this review of evidence, we developed an algorithm for the evaluation and treatment of patients who may be intolerant to statins as the result of adverse muscle events. The panel was composed of clinical cardiologists, clinical lipidologists, an exercise physiologist, and a neuromuscular specialist.
    Journal of Clinical Lipidology 05/2014; 8(3 Suppl):S58-71. DOI:10.1016/j.jacl.2014.03.004 · 3.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coenzyme Q10 (CoQ10) is an antioxidant, a membrane stabilizer, and a vital cofactor in the mitochondrial electron transport chain, enabling the generation of adenosine triphosphate. It additionally regulates gene expression and apoptosis; is an essential cofactor of uncoupling proteins; and has anti-inflammatory, redox modulatory, and neuroprotective effects. This paper reviews the known physiological role of CoQ10 in cellular metabolism, cell death, differentiation and gene regulation, and examines the potential repercussions of CoQ10 depletion including its role in illnesses such as Parkinson's disease, depression, myalgic encephalomyelitis/chronic fatigue syndrome, and fibromyalgia. CoQ10 depletion may play a role in the pathophysiology of these disorders by modulating cellular processes including hydrogen peroxide formation, gene regulation, cytoprotection, bioenegetic performance, and regulation of cellular metabolism. CoQ10 treatment improves quality of life in patients with Parkinson's disease and may play a role in delaying the progression of that disorder. Administration of CoQ10 has antidepressive effects. CoQ10 treatment significantly reduces fatigue and improves ergonomic performance during exercise and thus may have potential in alleviating the exercise intolerance and exhaustion displayed by people with myalgic encepholamyletis/chronic fatigue syndrome. Administration of CoQ10 improves hyperalgesia and quality of life in patients with fibromyalgia. The evidence base for the effectiveness of treatment with CoQ10 may be explained via its ability to ameliorate oxidative stress and protect mitochondria.
    Molecular Neurobiology 06/2013; 48(3). DOI:10.1007/s12035-013-8477-8 · 5.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The SELA board decided to devote this issue of Lipid Spin to the problem of statin intolerance. In formal clinical trials statin intolerance is reported in 2 to 3 percent of study subjects, but longer term follow up studies report a more realistic rate of 15 to 20 percent. In an informal survey of the past-president’s (PZ) private practice lipid clinic 24 of the most recent 30 new patients were referred because of statin intolerance. The most common problems reported by statin intolerant patients are muscle complaints (about 80%), but the full spectrum of statin intolerance includes increased liver enzymes, allergic reaction, headache, neuropathy, alopecia, memory disturbances, glucose intolerance, gastrointestinal disturbances, insomnia, arthralgias, exercise intolerance, depression and dizziness. Also, patients with statin intolerance are at a clinical and economic disadvantage. In with an 80 percent relative risk myocardial infarctions and a 53 percent relative risk increase for all cause mortality compared to similar patients able to tolerate statins. Dyslipidemic patients unable to take statins have been reported to incur a $400 to $900 greater total health care cost over an 18 month observation period compared to similar patients able to tolerate statin therapy. This issue of Lipid Spin will examine some of the clinical strategies used to deal with statin intolerance, including switching to statins with a better tolerability profile, use of very low dose - low frequency statin , vitamin D supplementation, CoQ10 supplementation and the use ofnon-statin lipid lowering regimens.
    NLA Lipid Spin, Fall 2013; 11/2013
Show more